Cooper Companies (NASDAQ:COO) Hits New 52-Week Low – What’s Next?

The Cooper Companies, Inc. (NASDAQ:COO)’s share price reached a new 52-week low on Tuesday . The stock traded as low as $58.91 and last traded at $58.98, with a volume of 1696336 shares traded. The stock had previously closed at $60.00.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Rothschild & Co Redburn downgraded shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a research report on Wednesday, March 4th. Citigroup dropped their target price on shares of Cooper Companies from $88.00 to $87.00 and set a “neutral” rating on the stock in a research report on Friday, March 6th. William Blair raised shares of Cooper Companies to a “strong-buy” rating in a research report on Friday, January 30th. Barclays lifted their target price on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, March 6th. Finally, Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cooper Companies has a consensus rating of “Moderate Buy” and an average price target of $90.79.

Cooper Companies Price Performance

The stock’s 50-day moving average is $70.21 and its 200 day moving average is $75.86. The stock has a market capitalization of $11.51 billion, a PE ratio of 29.20, a P/E/G ratio of 1.55 and a beta of 0.89. The company has a quick ratio of 0.79, a current ratio of 1.34 and a debt-to-equity ratio of 0.22.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.07. Cooper Companies had a net margin of 9.67% and a return on equity of 10.34%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the firm posted $0.92 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, equities analysts predict that The Cooper Companies, Inc. will post 4.62 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COO. Wellington Management Group LLP grew its position in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after purchasing an additional 4,756,178 shares in the last quarter. Generation Investment Management LLP purchased a new position in Cooper Companies during the fourth quarter valued at approximately $233,539,000. Diamond Hill Capital Management Inc. grew its position in Cooper Companies by 479.6% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,287,837 shares of the medical device company’s stock valued at $269,471,000 after purchasing an additional 2,720,594 shares in the last quarter. JANA Partners Management LP purchased a new position in Cooper Companies during the third quarter valued at approximately $166,917,000. Finally, Price T Rowe Associates Inc. MD grew its position in Cooper Companies by 58.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock valued at $494,123,000 after purchasing an additional 2,231,568 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.